PolyPeptide Group AG (PPGN) - Cash Flow Conversion Efficiency
Based on the latest financial reports, PolyPeptide Group AG (PPGN) has a cash flow conversion efficiency ratio of 0.150x as of June 2025. Cash flow conversion efficiency measures how effectively a company's net assets (equity) generate operating cash flow. It is calculated by dividing operating cash flow (CHF49.66 Million ≈ $62.78 Million USD) by net assets (CHF330.99 Million ≈ $418.45 Million USD). A higher ratio indicates that the company is more efficient at using its equity to generate cash flow from its core operations. Also see market cap of PolyPeptide Group AG for the company's overall valuation and market capitalisation.
PolyPeptide Group AG - Cash Flow Conversion Efficiency Trend (2018–2024)
This chart illustrates how PolyPeptide Group AG's cash flow conversion efficiency has evolved over time, based on yearly financial data. View PolyPeptide Group AG (PPGN) stock price for real-time trading data and today's change.
PolyPeptide Group AG Competitors by Cash Flow Conversion Efficiency
The table below lists competitors of PolyPeptide Group AG ranked by their cash flow conversion efficiency. Review cash generation quality of PolyPeptide Group AG to assess how much free cash flow the company generates relative to operating cash flow.
| Company | Cash Flow Conversion Efficiency |
|---|---|
|
Nano Nuclear Energy Inc. Common Stock
NASDAQ:NNE
|
-0.022x |
|
Grocery Outlet Holding Corp
NASDAQ:GO
|
0.091x |
|
Barrett Business Services Inc
NASDAQ:BBSI
|
0.160x |
|
Hunan Jiudian Pharmaceutical Co Ltd
SHE:300705
|
0.066x |
|
Shenzhen Feima International Supply Chain Co Ltd
SHE:002210
|
0.042x |
|
Jiangsu Huachang Chemical Co Ltd
SHE:002274
|
0.011x |
|
Xianheng International Science & Technology Co Ltd
SHG:605056
|
N/A |
|
Union Optech Co Ltd
SHE:300691
|
0.002x |
Annual Cash Flow Conversion Efficiency for PolyPeptide Group AG (2018–2024)
The table below shows the annual cash flow conversion efficiency of PolyPeptide Group AG from 2018 to 2024. Also see PPGN total assets for a full breakdown of the balance sheet.
| Year | Net Assets | Operating Cash Flow | Cash Flow Conversion Efficiency | Change |
|---|---|---|---|---|
| 2024-12-31 | CHF357.24 Million ≈ $451.65 Million |
CHF89.40 Million ≈ $113.02 Million |
0.250x | +161.48% |
| 2023-12-31 | CHF381.23 Million ≈ $481.97 Million |
CHF36.48 Million ≈ $46.13 Million |
0.096x | +639.13% |
| 2022-12-31 | CHF421.68 Million ≈ $533.11 Million |
CHF5.46 Million ≈ $6.90 Million |
0.013x | -90.49% |
| 2021-12-31 | CHF421.17 Million ≈ $532.48 Million |
CHF57.35 Million ≈ $72.51 Million |
0.136x | -51.11% |
| 2020-12-31 | CHF177.66 Million ≈ $224.61 Million |
CHF49.48 Million ≈ $62.56 Million |
0.279x | -25.15% |
| 2019-12-31 | CHF149.42 Million ≈ $188.90 Million |
CHF55.60 Million ≈ $70.29 Million |
0.372x | +139.51% |
| 2018-12-31 | CHF147.67 Million ≈ $186.70 Million |
CHF22.94 Million ≈ $29.01 Million |
0.155x | -- |
About PolyPeptide Group AG
PolyPeptide Group AG operates as a contract development and manufacturing company in Europe, the United States, and India. It develops and manufactures synthetic peptides and oligonucleotides used as active pharmaceutical ingredients or intermediates in therapeutic products for pharmaceutical and biotech companies. The company offers portfolio of drug therapies for metabolic diseases, including t… Read more